Frequency of CD4+CD25+Foxp3+ Cells in Peripheral Blood in Relation to Urinary Bladder Cancer Malignancy Indicators Before and After Surgical Removal

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Feb 11

PMID 26862849

Citations 18

Authors

Wojciech Jozwicki

Anna A Brozyna

Jerzy Siekiera

Andrzej T Slominski

Affiliations

Soon will be listed here.

Abstract

Tumor cells communicate with stromal cells, including cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs), to form microenvironment inhibiting immune responses. Regulatory T cells (Tregs, CD4+CD25+FoxP3+) stimulate immune tolerance and facilitate tumor progression. We analyzed the changes in Treg frequencies assessed using flow cytometry in the peripheral blood of patients with urothelial bladder cancer before and after tumor-removal. Changes in Treg frequency were investigated in relation to clinicopathomorphological indicators of tumor malignancy and expression of RCAS1 on CAFs and TAMs. Higher Treg frequencies were observed in early phase of tumor growth (pTa-pT2), in larger tumors, with more aggressive type of invasion, and with expression of RCAS1. The later phase of tumor development, accompanied by a nonclassic differentiations and pT3-pT4 advancement, had lower number of tumor infiltrating lymphocytes (TILs) and lower Treg frequency. Furthermore, in pT2-pT4 tumors, a decreased post-surgery Treg frequency was associated with poorer prognosis: patients with the lowest frequency of Tregs died first. These findings strongly suggest that the Treg frequencies at later phase of tumor growth, associated with a low anti-tumor response, represent a new and important prognostic indicator in urinary bladder cancer.

Citing Articles

Nucleotide variation in Foxp3 gene and prognosis of bladder cancer: a case-control study.

Li Q, Zhang Y, Su M, Song Y, Wang Y, Zhou B Front Oncol. 2025; 15:1506900.

PMID: 39935826 PMC: 11810724. DOI: 10.3389/fonc.2025.1506900.

Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.

Bhattacharya S, Paraskar G, Jha M, Gupta G, Prajapati B ACS Pharmacol Transl Sci. 2024; 7(8):2215-2236.

PMID: 39144553 PMC: 11320738. DOI: 10.1021/acsptsci.4c00156.

Exosomes-Promising Carriers for Regulatory Therapy in Oncology.

Jozwicka T, Erdmanska P, Stachowicz-Karpinska A, Olkiewicz M, Jozwicki W Cancers (Basel). 2024; 16(5).

PMID: 38473285 PMC: 10931160. DOI: 10.3390/cancers16050923.

Peripheral T cell profiling reveals downregulated exhaustion marker and increased diversity in lymphedema post-lymphatic venous anastomosis.

Imai H, Kawase T, Yoshida S, Mese T, Roh S, Fujita A iScience. 2023; 26(6):106822.

PMID: 37250774 PMC: 10212982. DOI: 10.1016/j.isci.2023.106822.

Tumor microenvironment and epithelial-mesenchymal transition in bladder cancer: Cytokines in the game?.

Martins-Lima C, Chianese U, Benedetti R, Altucci L, Jeronimo C, Correia M Front Mol Biosci. 2023; 9:1070383.

PMID: 36699696 PMC: 9868260. DOI: 10.3389/fmolb.2022.1070383.

References

Jozwicki W, Brozyna A, Siekiera J . Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression. Int J Mol Sci. 2014; 15(9):16069-82. PMC: 4200762. DOI: 10.3390/ijms150916069. View

Yu P, Fu Y . Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest. 2006; 86(3):231-45. DOI: 10.1038/labinvest.3700389. View

Strauss L, Bergmann C, Gooding W, Johnson J, Whiteside T . The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007; 13(21):6301-11. DOI: 10.1158/1078-0432.CCR-07-1403. View

Hasegawa T, Suzuki H, Yamaura T, Muto S, Okabe N, Osugi J . Prognostic value of peripheral and local forkhead box P3 regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014; 2(5):685-694. PMC: 4106667. DOI: 10.3892/mco.2014.299. View

Lim K, Chun N, Ismail S, Abraham M, Yusoff M, Zain R . CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients. PLoS One. 2014; 9(8):e103975. PMC: 4143252. DOI: 10.1371/journal.pone.0103975. View

Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K . Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med. 2005; 201(5):681-6. PMC: 2212825. DOI: 10.1084/jem.20041959. View

Akashi T, Oimomi H, Nishiyama K, Nakashima M, Arita Y, Sumii T . Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas. 2002; 26(1):49-55. DOI: 10.1097/00006676-200301000-00009. View

Joyce J . Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005; 7(6):513-20. DOI: 10.1016/j.ccr.2005.05.024. View

Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson J, Whiteside T . A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007; 13(15 Pt 1):4345-54. DOI: 10.1158/1078-0432.CCR-07-0472. View

10.

Wang H, Wang R . Regulatory T cells and cancer. Curr Opin Immunol. 2007; 19(2):217-23. DOI: 10.1016/j.coi.2007.02.004. View

11.

Baecher-Allan C, Brown J, Freeman G, Hafler D . CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001; 167(3):1245-53. DOI: 10.4049/jimmunol.167.3.1245. View

12.

Sonoda K, Miyamoto S, Nakashima M, Wake N . The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci. 2007; 13:1106-16. DOI: 10.2741/2748. View

13.

Wicherek L, Jozwicki W, Windorbska W, Roszkowski K, Lukaszewska E, Wisniewski M . Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer - a preliminary report. Am J Reprod Immunol. 2011; 66(5):444-50. DOI: 10.1111/j.1600-0897.2011.01024.x. View

14.

Ascierto P, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A . Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010; 8:76. PMC: 2936304. DOI: 10.1186/1479-5876-8-76. View

15.

Khattri R, Cox T, Yasayko S, Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003; 4(4):337-42. DOI: 10.1038/ni909. View

16.

Dutsch-Wicherek M, Kazmierczak W . Creation of a suppressive microenvironment by macrophages and cancer-associated fibroblasts. Front Biosci (Landmark Ed). 2013; 18(3):1003-16. DOI: 10.2741/4159. View

17.

Wang Z, Yang B, Liu H, Hu Y, Yang J, Wu L . Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother. 2011; 61(6):911-6. PMC: 11029076. DOI: 10.1007/s00262-011-1158-4. View

18.

DAmbrosio D . Regulatory T cells: how do they find their space in the immunological arena?. Semin Cancer Biol. 2005; 16(2):91-7. DOI: 10.1016/j.semcancer.2005.11.002. View

19.

Domanowska E, Jozwicki W, Domaniewski J, Golda R, Skok Z, Wisniewska H . Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol. 2007; 38(5):741-6. DOI: 10.1016/j.humpath.2006.11.001. View

20.

Bursuker I, NORTH R . Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer. 1986; 37(2):275-81. DOI: 10.1002/ijc.2910370216. View